Study finds no significant survival benefit from participating in cancer clinical trials

FHS
May 23, 2024
8:19 pm

Participation in cancer clinical trials often suggests improved survival rates, but high-quality studies accounting for biases show no significant survival benefit. Trial benefits may be overstated due to confounding factors.

Teva, Royalty Pharma to expedite olanzapine LAI programme

Share this article Olanzapine LAI is being analysed in a Phase III trial to treat schizophrenia. Credit: Doidam 10 / Shutterstock.com Teva Pharmaceuticals has entered a

November 14, 2023

Salvage RT After Prostatectomy Prevails in Long-Term Comparison With Adjuvant RT

Adjuvant radiotherapy (RT) after radical prostatectomy did not improve outcomes in prostate cancer as compared with salvage RT but added toxicity, according to long-term follow-up

April 20, 2024

Researchers call for Medicare to cover driving safety evaluations of at-risk, older adults

In 2020, approximately 48 million licensed drivers were older than 65 years. Within this age group, car crashes led to 7,480 deaths and 149,881 non-fatal

August 12, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.